The c-Met/HGF signaling pathway is implied in carcinogenesis and progression of HCC [18, 19].In a randomized phase II trial in patients with advanced HCC for whom sorafenib or sunitinib failed, tivantinib showed a significant improvement in TTP (primary endpoint) compared with placebo (median 1.6 vs. 1.4 months, HR = 0.64, 95% CI: 0.43–0.94, P = 0.04) [12]. This evidence concerns the gene MET and hepatocellular carcinoma.